Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.25    -0.25 (-2.94%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £58.17m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

TR-1

23 Jul 2021 13:26

RNS Number : 3269G
Poolbeg Pharma PLC
23 July 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Poolbeg Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Schroders PLC

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

21/07/2021

6. Date on which issuer notified (DD/MM/YYYY):

22/07/2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuervii

Resulting situation on the date on which threshold was crossed or reached

5.128388%

N/A

5.128388%

25,641,941

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BKPG7Z60

25,641,941

5.128388%

SUBTOTAL 8. A

25,641,941

5.128388%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Schroders PLC

Schroder Administration Limited

Schroder Wealth Holdings Limited

Schroder & Co. Limited

Schroders plc

Schroder Administration Limited

Schroder International Holdings Limited

Schroder Investment Management Limited

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

22/07/2021

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLDKNBBBBKDQOB
Date   Source Headline
26th May 20227:00 amRNSUS patents granted for POLB 001 and POLB 002
25th May 20224:40 pmRNSSecond Price Monitoring Extn
25th May 20224:35 pmRNSPrice Monitoring Extension
23rd May 20221:01 pmRNSTR-1: Notification of major interest in shares
12th May 20227:00 amRNSGMP manufacturing contract signed
11th May 20227:00 amRNSAttendance at European Melioidosis Congress
27th Apr 20227:00 amRNSDistribution in Specie update
14th Apr 20227:00 amRNSKey POLB 002 European Patent Granted
11th Apr 20227:00 amRNSDistribution in Specie Shareholders
4th Apr 202212:26 pmRNSResult of AGM
31st Mar 20227:00 amRNSPOLB001 Update - Clinical Trial Agreement Signed
30th Mar 20227:00 amRNSCommencement of trading on US OTCQB market
24th Mar 20227:00 amRNSAI deal signed with CytoReason
9th Mar 20227:00 amRNSNotice of AGM
3rd Mar 20227:00 amRNSFinal Results
28th Feb 20227:00 amRNSNotice of Results
24th Feb 20227:00 amRNSArtificial Intelligence deal with OneThree Biotech
31st Jan 20227:00 amRNSConfirmation of vaccine platform licence execution
17th Jan 20227:00 amRNSExclusive license of RNA-based immunotherapy asset
16th Dec 20217:00 amRNSPoolbeg to develop oral vaccine delivery platform
6th Dec 20217:00 amRNSPoolbeg signs option for new vaccine candidate
25th Nov 20217:00 amRNSScientific Advisory Board Appointment
18th Nov 20217:00 amRNSUpdate on POLB 001 Clinical Development
14th Oct 20219:05 amRNSSecond Price Monitoring Extn
14th Oct 20219:00 amRNSPrice Monitoring Extension
14th Oct 20217:00 amRNSPredictViral Patent Update
7th Oct 20217:00 amRNSRNA sequencing ahead of AI analysis programme
13th Sep 20217:00 amRNSSeptember and October Investor conferences
7th Sep 20217:00 amRNSPOLB001 US Patent Update
23rd Aug 20219:06 amRNSSecond Price Monitoring Extn
23rd Aug 20219:00 amRNSPrice Monitoring Extension
4th Aug 202111:30 amRNSHolding(s) in Company
23rd Jul 20211:26 pmRNSTR-1
19th Jul 20217:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.